Pipeline

Medigene’s proprietary end-to-end platform enables the development of differentiated, best-in class T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Medigene develops these therapies on its own or in partnership.

  • Discovery Stage
  • CTA/IND-enabling
  • Clinical Studies
Upcoming Milestone

Multiple Solid Tumor Types

NY-ESO-1 + PD1-41BB / HLA-A2

MDG1015

CTA / IND 2H 2024

Medigene’s lead candidate targeting NY-ESO-1 combined with our PD1-41BB costimulatory switch receptor. 

Read More

Undisclosed Targets / Undisclosed HLAs + PD1-41BB

MDG10XX

Lead selection 2H 2023

Generation of TCR T cells targeting appropriate antigens with several different HLA types each developed and improved with our optimization technologies and combined with our PD1-41BB costimulatory switch receptor.

PRAME / HLA-A2

Milestones set by BioNtech

Exclusively partnered with BioNtech.  Also includes non-exclusive licenses to our optimization technologies

MAGE-A4 / HLA-A2

Milestones set by 2seventy bio

Exclusively partnered with 2seventy bio.

NY-ESO-1 / HLA-A2

Milestones set by Hongsheng Sciences

Exclusively partnered with Hongsheng Sciences.

Multiple Liquid Tumor Types

PRAME / HLA-A2

MDG1011

NY-ESO-1 / HLA-A2

Milestones set by Hongsheng Sciences

Exclusively partnered with Hongsheng Sciences.

INTELLECTUAL PROPERTY

Medigene’s proprietary “end-to-end” platform for identifying, selecting and engineering best-in-class TCRs is protected by exclusively in-licensed and proprietary patents in Europe, North America and Japan. Patent rights individually protect all TCRs generated by our proprietary TCR platform technology in countries selected based on our corporate commercial long-term strategy. In addition, Medigene is constantly developing improved methods and technologies across our “end-to-end “platform to produce the best TCR therapies. These methods are also subject to new patent protection in line with our company’s patent strategy.